Abstract
Tumor lysis syndrome (TLS) is a potential life-threatening complication in cancer therapy, although it is rare in nonhematologic malignancy. Sorafenib, an oral multi tyrosine kinase inhibitor, has demonstrated survival benefit for patients with advanced hepatocellular carcinoma (HCC). A 70-year-old man with massive HCC was treated with sorafenib. Seven days after the start of treatment, he developed acute renal failure and elevation of hepatic enzymes, suggesting TLS. Abdominal CT depicted multiple hemorrhages in his liver. He was treated with emergent hemodialysis. He was discharged from the hospital, but mild renal dysfunction remained. We should pay careful attention to treatment of patients who have large HCC with sorafenib.
This is a preview of subscription content, log in via an institution to check access.
References
Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099–7109
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390
Huang W-S, Yang C-H (2009) Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World J Gastroenterol WJG 15(35):4464
Joshita S, Yoshizawa K, Sano K et al (2010) A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. Intern Med 49(11):991–994
Shiozawa K, Watanabe M, Takenaka H et al (2010) Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report. Hepatogastroenterology 57(101):688–690
Abbass K, Dewani S, Markert R et al (2011) All that glitters: sorafenib. Intern Med 50(7):797
Habib G, Nashashibi M (2013) Fatal tumor lysis syndrome following sorafenib treatment. J Med Cases 4(4):269–270
Cairo MS, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127(1):3–11
Oncology JSoM (ed) (2013) Tumor lysis syndrome guidance, vol 1. Kanehara Shuppan, Tokyo
Gemici C (2006) Tumour lysis syndrome in solid tumours. Clin Oncol 18(10):773–780
Baeksgaard L, Sorensen JB (2003) Acute tumor lysis syndrome in solid tumors—a case report and review of the literature. Cancer Chemother Pharmacol 51(3):187–192
Coiffier B, Altman A, Pui CH et al (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26(16):2767–2778
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kudo, C., Miura, M., Gamoh, M. et al. Tumor lysis syndrome after treatment with sorafenib for hepatocellular carcinoma. Int Canc Conf J 4, 147–150 (2015). https://doi.org/10.1007/s13691-014-0186-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-014-0186-2